{
    "clinical_study": {
        "@rank": "82269", 
        "arm_group": [
            {
                "arm_group_label": "Quitiapine plus Omega", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks"
            }, 
            {
                "arm_group_label": "Quetiapine plus Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will be randomized to similar in shape an color placebo supplements (corn oil)"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will test the hypothesis that the adverse effects of second-generation\n      antipsychotics exposure and the beneficial effects of long-chain omega-3 (LCn-3) fatty acids\n      are mediated by opposing effects on the enzyme implicated in the metabolic syndrome and\n      obesity."
        }, 
        "brief_title": "SGA-induced Metabolic Syndrome in Bipolar Youth", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar Youth Treated With Second-generation Antipsychotics", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "detailed_description": {
            "textblock": "This will be a two-phase study design:\n\n      Phase I:  to prospectively investigate the relationship between baseline LCn-3 fatty acid\n      status and treatment-emergent adverse cardiometabolic events and weight gain in response to\n      acute (6-week) open-label quetiapine in first-episode adolescent manic patients (ages 12-17\n      years). SGA-na\u00efve acutely manic patients will be treated with open-label quetiapine for\n      6-weeks. Patients will be started on 100 mg BID of quetiapine, and the dose adjusted based\n      on tolerability and response. The quetiapine target dose is 400-600 mg, with subjects in the\n      range of 200-500 mg.\n\n      Phase II: Patients from Phase I will be randomized to double-blind adjunctive treatment with\n      LCn-3 fatty acids or placebo for an additional 24 weeks to investigate protective effects on\n      the progression and resolution of adverse cardiometabolic events and weight gain during\n      quetiapine maintenance therapy. They will have 6 visits over a 24-week period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  DSM-IV-TR criteria for bipolar disorder, type I, manic or mixed episode\n\n          -  Baseline YMRS score > 20\n\n          -  Ages 10-17 years\n\n          -  Tanner scale stages III-V\n\n          -  No prior exposure to SGA medications\n\n          -  Fluent in English\n\n          -  Provision of written informed consent by a legal guardian and written assent by the\n             subject\n\n          -  Manic or depressive symptoms do not result entirely from acute medical illness or\n             acute intoxication or withdrawal from drugs or alcohol as determined by medical\n             evaluation and rapid symptom resolution\n\n          -  If female and of child bearing potential, agrees to use one of the following method\n             of birth control: complete abstinence from sexual intercourse, barrier (diaphragm or\n             condom), or oral/injectable contraceptive. For Phase II, additional Inclusion\n             criteria are\n\n          -  Receiving a stable therapeutic dose of quetiapine for a minimum of 1 week (i.e.,\n             patients who achieved remission (YMRS total score 7 during Phase I)\n\n          -  Not requiring concomitant use of antidepressant or mood-stabilizer medications (see\n             Section C.4.c. Concomitant Medications).\n\n        Exclusion Criteria:\n\n          -  IQ < 70, as determined by The Wechsler Abbreviated Scale of Intelligence\n\n          -  Positive pregnancy test (to avoid teratogenesis)\n\n          -  A history of major cardiovascular or neurological illness\n\n          -  Any lifetime DSM-IV-TR substance use disorder (nicotine dependence is permitted)\n\n          -  A lifetime DSM-IV-TR diagnosis of any pervasive developmental disorder\n\n          -  Any history of a hematological disorder in themselves or a first-degree relative will\n             be excluded (since omega-3 fatty acids may be associated with anti-thrombotic\n             effects). Similarly, concomitant use of medications with anticoagulant effects (e.g.\n             aspirin) will be prohibited\n\n          -  Allergy to fish/seafood; 8) Currently taking omega-3 fatty acid supplements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858948", 
            "org_study_id": "DK097599-01A1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Quitiapine plus Omega", 
                "description": "Omega-3 supplements", 
                "intervention_name": "Omega", 
                "intervention_type": "Drug", 
                "other_name": "EPA+DHA supplements (OmegaRx)"
            }, 
            {
                "arm_group_label": "Quetiapine plus Placebo", 
                "description": "Similar in shape and color to Omega supplements", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo supplements (corn oil) provided by the Inflammation Research Foundation"
            }, 
            {
                "arm_group_label": [
                    "Quitiapine plus Omega", 
                    "Quetiapine plus Placebo"
                ], 
                "description": "Patients will be started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.", 
                "intervention_name": "Quetiapine fumarate", 
                "intervention_type": "Drug", 
                "other_name": "Seroquel"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bipolar disorder", 
            "Second-generation antipsychotics", 
            "Obesity", 
            "Cardiometabolic risk"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "email": "robert.mcnamara@uc.edu", 
                "last_name": "Robert K McNamara, PhD", 
                "phone": "513-558-5601"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45219"
                }, 
                "name": "University of Cincinnati"
            }, 
            "investigator": [
                {
                    "last_name": "Robert K McNamara, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Robert K McNamara, Ph.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Risk and Protective Factors for SGA-induced Metabolic Syndrome in Bipolar Youth", 
        "other_outcome": {
            "description": "Side Effects Form for Children and Adolescents (SEFCA), which measures the frequency and severity of specific cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nasal, genitourinary, dermatological, and musculoskeletal side effects", 
            "measure": "SEFCA", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "overall_contact": {
            "email": "imhofflr@ucmail.uc.edu", 
            "last_name": "Laura R Imhoff", 
            "phone": "513-558-7700"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Robert K McNamara, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Body Mass Index, which is a measure of body fat based on height and weight.  Calculated as weight in kilograms divided by height in meters squared (kg/m2)", 
                "measure": "BMI", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Triglycerides are the chemical form in which most fat exists in food as well as in the body. They're also present in blood plasma and, in association with cholesterol, form the plasma lipids.", 
                "measure": "Fasting Triglycerides", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858948"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Robert McNamara", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Symptom ratings will be obtained using the Young Mania Rating Scale (YMRS)", 
            "measure": "Mood Symptoms", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "source": "University of Cincinnati", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}